Dostarlimab (TSR-042) clinical trials

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

This study compares new drug combinations (dostarlimab and niraparib) with standard care for women newly diagnosed with advanced ovarian cancer. It aims to see if these new treatments can stop the cancer from growing for longer.